Dental Pain Clinical Trial
Official title:
Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain
NCT number | NCT01420653 |
Other study ID # | AFT-MX-6 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | April 2013 |
Est. completion date | January 2015 |
Verified date | January 2015 |
Source | AFT Pharmaceuticals, Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.
Status | Completed |
Enrollment | 408 |
Est. completion date | January 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Provides written informed consent before initiation of any study-related procedures. - Males and females aged at least 10 years and not more than 60 years old on the day of consent. - Undergoing dental surgery for the extraction of at least 2 impacted third molar teeth. - A resting VAS pain intensity score at baseline (within 6 hours after the completion of surgery) of greater than or equal to 40 mm on a 100 mm VAS scale with 0 = no pain and 100 = worst pain imaginable. Exclusion Criteria: - Has taken any NSAID or acetaminophen within 12 hours prior to the stat of surgery other than asprin less than or equal to 150 mg/day - Subjects who have received any anaesthetics within 24 hours prior to surgery - Hypersensitivity to opioids - Known to be pregnant or possibly pregnant - Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A women of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy. - Women of childbearing potential who are unwilling to undergo an urine pregnancy test. - Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective. - In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements. - Currently, or in the last 30 days, has been in a clinical trial involving another study drug. - Currently treated with an ACE inhibitor, warfarin, steroid (other than nasal steroids or topical steroids with the approval of the investigator) cyclosporin, tacrolimus or methotrexate, or any other medication felt by the investigator to interfere with safety or efficacy evaluations. - Participant weight < 50 kg or > 120 kg. - Has a history of drug or alcohol abuse. - Suffering from any other disease or condition which, in the opinion of the investigator, means that it would not be in the participants best interests to participant in the study. |
Country | Name | City | State |
---|---|---|---|
New Zealand | Clinical Solutions Ltd. | Auckland | |
New Zealand | Southern Clinical Trials | Christchurch | |
New Zealand | Clinical Trial New Zealand | Hamilton | Waikato |
United States | Premier Research | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
AFT Pharmaceuticals, Ltd. |
United States, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SPID (Summed Pain Intensity Differences) | The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication. This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference. |
48 hours afte the first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00942448 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT00943098 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT00985439 -
Study of Diclofenac Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT00954356 -
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
|
Phase 2 | |
Completed |
NCT02966067 -
A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery
|
N/A | |
Completed |
NCT01960114 -
Study of Long-Acting Acetaminophen in Postoperative Dental Pain
|
Phase 2 | |
Completed |
NCT01229228 -
Study of Naproxen Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT01177423 -
Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block
|
N/A | |
Completed |
NCT03328208 -
Nonpharmacologic Reduction of Periprocedural Distress and Drug Use
|
N/A | |
Completed |
NCT05236101 -
Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety
|
N/A | |
Completed |
NCT00542035 -
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
|
Phase 2 | |
Completed |
NCT04231955 -
Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth
|
N/A | |
Completed |
NCT02096926 -
Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery
|
Phase 4 | |
Completed |
NCT05369936 -
Pain Perception: on Relationships Between Dental Anxiety and Olfaction
|
N/A | |
Recruiting |
NCT05351099 -
Dental Block for Pain Relief in ED Dental Pain Patients
|
||
Not yet recruiting |
NCT06269406 -
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
|
N/A | |
Recruiting |
NCT05443009 -
Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction
|
Phase 4 | |
Terminated |
NCT02161354 -
Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars
|
Phase 2 | |
Completed |
NCT04949126 -
Self Medication in Odontology (AUDE)
|
||
Completed |
NCT03652818 -
Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
|
Phase 2 |